Abstract 8P
Background
Tumor metabolism and tumor-specific immune responses are one of integral compartments consisting of tumor niche. Several lines of evidence showed that tumor cells and tumor-infiltrating lymphocytes (TILs) compete for glucose in tumor microenvironment and that tumor metabolic parameter correlates with localized immune markers in several solid tumors. With this background, we compared standardized uptake value (SUV) of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET-CT) and stromal TILs in breast cancer (1≥cm).
Methods
Two hundred two patients were identified among those who underwent preoperative 18F-FDG-PET-CT and had tumor size equal to or larger than 1cm. Maximum SUV was obtained from 18F-FDG-PET-CT. Stromal TILs was evaluated according to standardized methodology proposed by the international TIL Working Group. We identified factors related with high TILs (≥40%) using multiple logistic-regression. All tumors were treatment-naïve.
Results
There was a significant but weak correlation between continuous SUV and continuous TILs (p = 0.002, R = 0.215). Mean TILs was significantly high in Ki-67 labeling index ≥14%, nuclear/histologic grade 3, and HER2-positive or triple-negative breast cancer (TNBC). In multivariable analysis, aggressive subtypes as HER2-positive or TNBC and continuous SUV were significantly associated with high TILs ≥40%.
Conclusions
We found that SUV was associated with TILs in breast cancer and provide clinical evidence that elevated glucose uptake of breast tumors may be affected by TILs in tumor micromileu.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract
174P - Progression of computer aided diagnosis on gastric cancer
Presenter: Yingyan Yu
Session: Poster display session
Resources:
Abstract